Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 804023, 6 pages
http://dx.doi.org/10.1155/2014/804023
Research Article

Methylation of DLEC1 Promoter Is a Predictor for Recurrence in Chinese Patients with Gastric Cancer

1Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China
2Department of Medical Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, China
3Clinical Genetics Laboratory, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, China
4Department of Pathology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, China
5Department of Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, China

Received 7 July 2014; Revised 19 November 2014; Accepted 24 November 2014; Published 9 December 2014

Academic Editor: Valeria Barresi

Copyright © 2014 Xiaobing Ye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Ü. Koç, E. Çetinkaya, E. B. Bostanci et al., “Diagnostic significance of serum eotaxin-1 level in gastric cancer patients,” Disease Markers, vol. 35, no. 5, pp. 363–367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Li, J. Cui, C.-H. Zhang et al., “High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma,” International Journal of Medical Sciences, vol. 10, no. 12, pp. 1689–1697, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. D. E. Guggenheim and M. A. Shah, “Gastric cancer epidemiology and risk factors,” Journal of Surgical Oncology, vol. 107, no. 3, pp. 230–236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Sano, M. Sasako, S. Yamamoto et al., “Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2767–2773, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. K. W. Kim, B. I. Choi, J. K. Han et al., “Postoperative anatomic and pathologic findings at CT following gastrectomy,” Radiographics, vol. 22, no. 2, pp. 323–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Whiting, T. Sano, M. Saka, T. Fukagawa, H. Katai, and M. Sasako, “Follow-up of gastric cancer: a review,” Gastric Cancer, vol. 9, no. 2, pp. 74–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Sun, X.-H. Su, Y.-S. Guan et al., “Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results,” World Journal of Gastroenterology, vol. 14, no. 29, pp. 4627–4632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. H. Sim, Y. J. Kim, D.-Y. Oh et al., “The role of PET/CT in detection of gastric cancer recurrence,” BMC Cancer, vol. 9, article 73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Park, W. J. Lee, H. K. Lim, K. W. Park, J. Y. Choi, and B.-T. Kim, “Detecting recurrence of gastric cancer: the value of FDG PET/CT,” Abdominal Imaging, vol. 34, no. 4, pp. 441–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. Costello, M. C. Frühwald, D. J. Smiraglia et al., “Aberrant CpG-island methylation has non-random and tumour-type-specific patterns,” Nature Genetics, vol. 24, no. 2, pp. 132–138, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001. View at Google Scholar · View at Scopus
  12. M. Esteller, “CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future,” Oncogene, vol. 21, no. 35, pp. 5427–5440, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Yamashita, Y. Tsujino, K. Moriguchi, M. Tatematsu, and T. Ushijima, “Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray,” Cancer Science, vol. 97, no. 1, pp. 64–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Kwong, J.-Y. Lee, K.-K. Wong et al., “Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer,” Neoplasia, vol. 8, no. 4, pp. 268–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. H. Kang, S. Lee, N.-Y. Cho et al., “DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis,” Laboratory Investigation, vol. 88, no. 2, pp. 161–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Ying, F. F. Poon, J. Yu et al., “DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers,” British Journal of Cancer, vol. 100, no. 4, pp. 663–669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Sobin and C. Wittekind, International Union Against Cancer: TNM Classification of Malignant Tumors, Wiley, New York, NY, USA, 2002.
  18. H. Zheng, H. Takahashi, Y. Murai et al., “Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray,” Journal of Clinical Pathology, vol. 60, no. 3, pp. 273–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Ishikawa, M. Kai, M. Tamari et al., “Sequence analysis of a 685-kb genomic region on chromosome 3p22-p21.3 that is homozygously deleted in a lung carcinoma cell line,” DNA Research, vol. 4, no. 1, pp. 35–43, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Al Sarakbi, S. Reefy, W. G. Jiang, T. Roberts, R. F. Newbold, and K. Mokbel, “Evidence of a tumour suppressor function for DLEC1 in human breast cancer,” Anticancer Research, vol. 30, no. 4, pp. 1079–1082, 2010. View at Google Scholar · View at Scopus
  21. Q. Zhang, J. Ying, J. Li et al., “Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage,” The Journal of Urology, vol. 184, no. 2, pp. 731–737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. T. J. Seng, N. Currey, W. A. Cooper et al., “DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma,” British Journal of Cancer, vol. 99, no. 2, pp. 375–382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Sasaki, Y. Hikosaka, and O. Kawano, “Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients,” Oncology Letters, vol. 1, no. 2, pp. 283–287, 2010. View at Google Scholar
  24. C. Montavon, B. S. Gloss, K. Warton et al., “Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer,” Gynecologic Oncology, vol. 124, no. 3, pp. 582–588, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. V. L. Costa, R. Henrique, and C. Jerónimo, “Epigenetic markers for molecular detection of prostate cancer,” Disease Markers, vol. 23, no. 1-2, pp. 31–41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Wang, Y. Long, Y. Xu et al., “Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer,” Gastroenterology Research and Practice, vol. 2014, Article ID 436985, 7 pages, 2014. View at Publisher · View at Google Scholar